Table 6. Patient’s characteristics.

Patient’s characteristics	N (%)
Age
Range	45–83
Median	63.92
Gender
Male	25/40 (62.5)
Female	15/40 (37.5)
Therapy
Bevacizumab	25/40 (65)
Cetuximab	9/40 (25)
No therapy	6/40 (10)
Line of therapy
First	20/34 (59)
Second	10/34 (29)
Third	4/34 (12)